- Home
- OZ vs GALT Comparison
OZ vs GALT Comparison
Compare OZ & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OZ
- GALT
- Stock Information
- Founded
- OZ 2020
- GALT 2000
- Country
- OZ United States
- GALT United States
- Employees
- OZ N/A
- GALT N/A
- Industry
- OZ
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- OZ
- GALT Health Care
- Exchange
- OZ Nasdaq
- GALT Nasdaq
- Market Cap
- OZ 234.8M
- GALT 232.3M
- IPO Year
- OZ N/A
- GALT N/A
- Fundamental
- Price
- OZ $64.05
- GALT $5.05
- Analyst Decision
- OZ
- GALT Strong Buy
- Analyst Count
- OZ 0
- GALT 3
- Target Price
- OZ N/A
- GALT $6.00
- AVG Volume (30 Days)
- OZ 5.0K
- GALT 276.6K
- Earning Date
- OZ 11-19-2025
- GALT 11-12-2025
- Dividend Yield
- OZ N/A
- GALT N/A
- EPS Growth
- OZ N/A
- GALT N/A
- EPS
- OZ N/A
- GALT N/A
- Revenue
- OZ $5,695,000.00
- GALT N/A
- Revenue This Year
- OZ N/A
- GALT N/A
- Revenue Next Year
- OZ N/A
- GALT N/A
- P/E Ratio
- OZ N/A
- GALT N/A
- Revenue Growth
- OZ 235.00
- GALT N/A
- 52 Week Low
- OZ $56.77
- GALT $0.73
- 52 Week High
- OZ $82.89
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- OZ 51.13
- GALT 69.16
- Support Level
- OZ $63.50
- GALT $4.56
- Resistance Level
- OZ $64.90
- GALT $4.84
- Average True Range (ATR)
- OZ 0.48
- GALT 0.31
- MACD
- OZ -0.02
- GALT 0.02
- Stochastic Oscillator
- OZ 64.27
- GALT 76.80
About OZ Belpointe PREP LLC Units
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.